XTRA:BAYNPharmaceuticals
How Investors May Respond To Bayer (XTRA:BAYN) Landmark OCEANIC-STROKE Phase III Anticoagulant Success
Bayer announced that the main results from its global Phase III OCEANIC-STROKE trial of investigational anticoagulant asundexian in secondary stroke prevention, which previously met its primary efficacy and safety endpoints, will be presented as late-breaking data at the American Stroke Association’s International Stroke Conference in New Orleans in early February 2026.
The scale of OCEANIC-STROKE, enrolling over 12,300 patients worldwide, underlines Bayer’s ambition to expand its...